CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.49, moving -0.2% from the previous trading session. This change lagged the S&P 500's 1.7% gain on the day. Elsewhere, the Dow ...

CRISPR Therapeutics AG (CRSP) closed the latest trading day at $49.59, indicating a -0.56% change from the previous session's end. The stock's change was less than the S&P 500's daily loss of 0.29%.

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare inherited illnesses that affect the function of a person's red blood cells. It ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...

Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end ...

Given all these factors, it seems reasonable to assume that Casgevy could grab at least a decent share, perhaps 20% of its ...

Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth ...

GOVT is a basic U.S. government bond index fund designed to replicate the performance of the ICE U.S. Treasury Core Bond ...

In addition, Vertex has partnered with CRISPR Therapeutics (CRSP) and received approval for Casgevy, a cell therapy treatment ...

MGK is a passively managed ETF that tracks the performance of the CRSP US Mega Cap Growth index. This index represents the ...